The target lesion primary patency (TLPP)1 and access circuit primary patency (ACPP)2 of the WRAPSODY® Cell-Impermeable Endoprosthesis (CIE) remain superior to percutaneous transluminal angioplasty (PTA) through 24 months

Asset acquisition would expand Merit’s Endoscopy portfolio with an innovative device to treat patients suffering from Barretts esophagus and other gastrointestinal disorders.

SCOUT Radar Localization use grows, supporting more successful surgeries and improved patient care.

Thin-wall design with superior insertion and unique sheath-securement solution to support successful radial access procedures and may aid in reducing arterial spasm and occlusion

The WRAPSODY CIE is designed to help physicians prolong functional vascular access in hemodialysis patients.

In the AVG cohort of the US pivotal trial, the Merit WRAPSODY Cell-Impermeable Endoprosthesis (CIE) achieved 60.2% target lesion primary patency (TLPP) at 12 months.

Merit Medical Releases 12-Month Efficacy Results of the WRAPSODY® Cell-Impermeable Endoprosthesis (CIE)

Merit Medical Rings Nasdaq Opening Bell to Celebrate 35-Year Partnership

Multicenter, prospective study designed to evaluate safety and efficacy of Bloom™ Micro Occluder System for treatment of patent ductus arteriosus in premature infants

Unique cell-impermeable1 design extends life-saving treatment for dialysis patients.

WRAPSODY achieves 82% target lesion primary patency at six months in the single-arm cohort of the US pivotal trial

Versatile analog device offers fast inflation and ease of use, streamlining patient care